Research and Evaluation

What We Do

• Research and evaluation design and implementation, including study management
• Collaborative proposal development
• Program, practice and policy evaluation
• Provider, patient and community intervention testing
• Readiness and needs assessments
• Study participant recruitment and retention

• Survey development and testing
• Qualitative and quantitative data collection and analysis
• Aggregation, cleaning and management of large linked datasets
• Epidemiological surveillance
• Policy and issue brief development
• Translation of findings for dissemination to broad audiences

Areas of Study

• Opioids, prescribing practices and pain management
• Substance use disorder prevention, treatment and recovery
• Health care systems and practice change interventions
• Harm reduction and overdose and infectious disease prevention
• Epidemiology, community health and social determinants of health

Our Work

• Intervention to Increase Naloxone Engagement and Distribution in Community Pharmacies (RESPOND to PREVENT)
  In partnership with Brandeis University, Oregon State University and University of Washington and supported by National Institute on Drug Abuse.
• Oregon Measure 110 Process and Outcome Evaluations
  In partnership with RTI International, Vital Strategies and Fletcher Group and supported by Chan Zuckerberg Initiative, Arnold Ventures Foundation and Health Resources & Services Administration.
• Oregon Youth and Young Adult Fentanyl Study
  We are conducting this study to learn more about what youth and young adults in Oregon know about fentanyl and pills. As drug overdoses involving fentanyl are rising in Oregon, we hope to better understand youth and young adults’ experiences and ideas to help create educational programs about fentanyl. In partnership with Oregon Health & Science University and Oregon Health Authority and supported by the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH) and the Substance Abuse and Mental Health Services Administration (SAMHSA).
• Overdose Data to Action — Evaluation of Oregon's Overdose Prevention Initiative
  In partnership with Oregon Health Authority Injury Violence and Prevention Program and supported by Centers for Disease Control and Prevention.
• Peer Recovery Initiated in Medical Establishments + Infectious Disease Testing and Linkage to Care (PRIME+)
  In partnership with Oregon Health Authority Health Systems Division and Acute and Communicable Disease Program and supported by Substance Abuse and Mental Health Services Administration.
• Peers Expanding Engagement in Methamphetamine Harm Reduction With Contingency Management (PEER-CM)
  In partnership with Oregon Health & Science University and Oregon Health Authority and supported by National Institutes of Health and Substance Abuse and Mental Health Services.
• Case Study: Tackling the Opioid Epidemic Through Community Engagement and Data Linkage
  Fragmented data makes it difficult for health professionals to develop informed policies, clinical guidelines and care decisions. Comagine Health created a robust comprehensive opioid risk registry for Oregon by bringing together multiple data owners and disparate datasets.
• Blog: Celebrating National Recovery Month
• Research Publications
• 2021-2022 Summary Report
• 2020 Annual Report

Why Comagine Health?

Comagine Health prioritizes community-responsive and collaborative study designs. We bring to our study partnerships:

• Strong relationships with health systems, clinics and community-based organizations
• Versatile team skills and flexible staffing to adapt to evolving study needs
• Ability to expand partners’ capacity, reach, dissemination and impact